FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:2466-2467 June 4, 2009 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Diacon, A. H. PubMed Citation

The development of TMC207 represents an important advance in the chemotherapy of tuberculosis. It is perhaps most amazing because of the defiantly unconventional nature of the effort. At virtually every step, from the original discovery of the diarylquinolines by screening for compounds that would kill Mycobacterium smegmatis, a saprophytic distant relative of M. tuberculosis, through the phase 2 study by Diacon et al. reported in this issue of the Journal (ClinicalTrials.gov number, NCT00449644 [ClinicalTrials.gov] ),¹ this effort flouted conventional wisdom about how to develop new drugs for tuberculosis.

It is also a humbling case study that is worth some reflection. Those . . . [Full Text of this Article]

Source Information

From the Tuberculosis Research Section, National Institute of Allergy and Infectious Diseases, Bethesda, MD.

This article has been cited by other articles:

• (2009). A New Drug for MDR-TB?. JWatch Infect. Diseases 2009: 2-2 [Full Text]